121 related articles for article (PubMed ID: 9750837)
1. Cost-effectiveness of whole-body PET imaging in non-small cell lung cancer and malignant melanoma.
von Schulthess GK; Steinert HC; Dummer R; Weder W
Acad Radiol; 1998 Sep; 5 Suppl 2():S300-2. PubMed ID: 9750837
[No Abstract] [Full Text] [Related]
2. Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: a decision analysis.
Scott WJ; Shepherd J; Gambhir SS
Ann Thorac Surg; 1998 Dec; 66(6):1876-83; discussion 1883-5. PubMed ID: 9930463
[TBL] [Abstract][Full Text] [Related]
3. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma.
Makler PT
J Nucl Med; 1997 Jul; 38(7):1173-4. PubMed ID: 9225819
[No Abstract] [Full Text] [Related]
4. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma.
Gambhir SS; Hoh CK; Phelps ME; Madar I; Maddahi J
J Nucl Med; 1996 Sep; 37(9):1428-36. PubMed ID: 8790186
[TBL] [Abstract][Full Text] [Related]
5. Decision-tree sensitivity analysis for cost-effectiveness of chest 2-fluoro-2-D-[(18)F]fluorodeoxyglucose positron emission tomography in patients with pulmonary nodules (non-small cell lung carcinoma) in Japan.
Kosuda S; Ichihara K; Watanabe M; Kobayashi H; Kusano S
Chest; 2000 Feb; 117(2):346-53. PubMed ID: 10669673
[TBL] [Abstract][Full Text] [Related]
6. [Cost-effectiveness of PET in the management algorithms of lung tumors: comparison of health economic data].
Dietlein M; Moka D; Weber K; Theissen P; Schicha H
Nuklearmedizin; 2001 Aug; 40(4):122-8. PubMed ID: 11556202
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS study.
Verboom P; van Tinteren H; Hoekstra OS; Smit EF; van den Bergh JH; Schreurs AJ; Stallaert RA; van Velthoven PC; Comans EF; Diepenhorst FW; van Mourik JC; Postmus PE; Boers M; Grijseels EW; Teule GJ; Uyl-de Groot CA;
Eur J Nucl Med Mol Imaging; 2003 Nov; 30(11):1444-9. PubMed ID: 14579081
[TBL] [Abstract][Full Text] [Related]
8. Medical economics of whole-body FDG PET in patients suspected of having non-small cell lung carcinoma--reassessment based on the revised Japanese national insurance reimbursement system.
Abe K; Kosuda S; Kusano S
Ann Nucl Med; 2003 Dec; 17(8):649-55. PubMed ID: 14971606
[TBL] [Abstract][Full Text] [Related]
9. HCFA's coverage instructions for lung PET. Health Care Financing Administration.
Smith WJ
J Nucl Med; 1998 Jul; 39(7):28N-30N. PubMed ID: 9669378
[No Abstract] [Full Text] [Related]
10. [Cost-effective PET investigations in oncology].
Kálvin B; Fekésházy A; Lengyel Z; Szakáll S; Agoston P; Lengyel E; Székely J; Galuska L; Trón L; Esik O
Magy Onkol; 2002; 46(3):203-23. PubMed ID: 12368917
[TBL] [Abstract][Full Text] [Related]
11. Effectively using evidence for decision analysis.
Shaw LJ
J Nucl Med; 1997 Jul; 38(7):1172-3. PubMed ID: 9225818
[No Abstract] [Full Text] [Related]
12. Cost-effectiveness of hybrid PET/CT for staging of non-small cell lung cancer.
Schreyögg J; Weller J; Stargardt T; Herrmann K; Bluemel C; Dechow T; Glatting G; Krause BJ; Mottaghy F; Reske SN; Buck AK
J Nucl Med; 2010 Nov; 51(11):1668-75. PubMed ID: 21051648
[TBL] [Abstract][Full Text] [Related]
13. Economic analyses on the use of positron emission tomography for the work-up of solitary pulmonary nodules and for staging patients with non-small-cell-lung-cancer in Italy.
Gugiatti A; Grimaldi A; Rossetti C; Lucignani G; De Marchis D; Borgonovi E; Fazio F
Q J Nucl Med Mol Imaging; 2004 Mar; 48(1):49-61. PubMed ID: 15195004
[TBL] [Abstract][Full Text] [Related]
14. [Decision tree sensitivity analysis for cost-effectiveness of chest FDG-PET in patients with a pulmonary tumor (non-small cell carcinoma)].
Kosuda S; Ichihara K; Watanabe M; Kobayashi H; Kusano S
Kaku Igaku; 1998 Jul; 35(6):395-404. PubMed ID: 9753918
[TBL] [Abstract][Full Text] [Related]
15. Accuracy and cost-effectiveness of [18F]-2-fluoro-deoxy-D-glucose-positron emission tomography scan in potentially resectable non-small cell lung cancer.
Kelly RF; Tran T; Holmstrom A; Murar J; Segurola RJ
Chest; 2004 Apr; 125(4):1413-23. PubMed ID: 15078754
[TBL] [Abstract][Full Text] [Related]
16. [PET with (18)F-fluorodeoxyglucose for staging of non-small cell lung cancer].
Weber WA; Dietlein M; Hellwig D; Kirsch CM; Schicha H; Schwaiger M
Nuklearmedizin; 2003 Aug; 42(4):135-44. PubMed ID: 12937692
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of FDG PET-CT in the management of pulmonary metastases from malignant melanoma.
Krug B; Crott R; Roch I; Lonneux M; Beguin C; Baurain JF; Pirson AS; Vander Borght T
Acta Oncol; 2010; 49(2):192-200. PubMed ID: 20059314
[TBL] [Abstract][Full Text] [Related]
18. Growth in the use of PET for six cancer types after coverage by medicare: additive or replacement?
Hillner BE; Tosteson AN; Song Y; Tosteson TD; Onega T; Goodman DC; Siegel BA
J Am Coll Radiol; 2012 Jan; 9(1):33-41. PubMed ID: 22221634
[TBL] [Abstract][Full Text] [Related]
19. 18FDG-PET-CT in the follow-up of non-small cell lung cancer patients after radical radiotherapy with or without chemotherapy: an economic evaluation.
van Loon J; Grutters JP; Wanders R; Boersma L; Dingemans AM; Bootsma G; Geraedts W; Pitz C; Simons J; Brans B; Snoep G; Hochstenbag M; Lambin P; De Ruysscher D
Eur J Cancer; 2010 Jan; 46(1):110-9. PubMed ID: 19944595
[TBL] [Abstract][Full Text] [Related]
20. [Whether and under what conditions FDG-PET might be cost-effective in evaluating solitary pulmonary nodules depicted on lung cancer screening in Japan].
Tsushima Y; Aoki J; Endo K
Nihon Igaku Hoshasen Gakkai Zasshi; 2003 Sep; 63(8):390-8. PubMed ID: 14587408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]